Inclusion Criteria:  Male and female patients with a confirmed diagnosis of vitiligo on the face and with Total-VASI > 10 and Facial-VASI of at least 0.25 Face vitiligo which is stable and has an onset of less than two years ago Stable or slowly progressive vitiligo over a 3-month period Fitzpatrick skin types IV-VI Previous treatment with Narrow-band Ultraviolet B (NB-UVB) light three times per week during the last four weeks prior to baseline Aged 18-75  Exclusion Criteria:  Patients with segmental vitiligo Patients with lip-tip (acrofacial) variant of vitiligo Fitzpatrick skin types I-III Patient not responsive to previous NB-UVB light treatment Previous topical treatment for vitiligo Allergy to afamelanotide or the polymer contained in the implant or to lignocaine/lidocaine or other local anaesthetic to be used during the administration of the implant History of melanoma or lentigo maligna Any current skin disease that may interfere with the study evaluation Presence of severe hepatic disease or hepatic impairment Renal impairment History of systemic or psychiatric disease judged to be clinically significant by the Investigator and which may interfere with the study evaluation Female who is pregnant or lactating Female of child-bearing potential not using adequate contraceptive measures during the treatment phase and for a period of three months thereafter Sexually active man with a partner of child-bearing potential who is not using adequate contraceptive measures, as described above Participation in a clinical trial for an investigational agent within 30 days prior to the Screening Visit Use of any other prior and concomitant therapy which may interfere with the objective of the study Subjects assessed as not suitable for the study in the opinion of the Investigator